THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY

被引：0
|
作者：
Tam, C. [1 ]
Roberts, A. [2 ]
Anderson, M. A. [2 ]
Dawson, S. J. [1 ]
Hicks, R. [1 ]
Pott, C. [3 ]
Westerman, D. [1 ]
Burke, G. [1 ]
Kamel, S. [4 ]
Dreyling, M. [5 ]
Dawson, M. [1 ]
Seymour, J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
[2] Melbourne Hlth, Parkville, Vic, Australia
[3] Univ Hosp Schleswig Holstein, Kiel, Germany
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Munich, Munich, Germany
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P316
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma
    Lee, Hun J.
    Badillo, Maria
    Romaguera, Jorge
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 460 - 462
  • [42] Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study.
    Goy, A
    Bernstein, S
    Kahl, B
    Epner, E
    Leonard, JP
    Stadtmauer, E
    Morgan, D
    Belt, R
    Baidas, S
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [43] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 664 - 665
  • [44] Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
    Touzeau, Cyrille
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Lebovic, Daniel
    Moreau, Philippe
    Darden, David E.
    Morris, Lura J.
    Ross, Jeremy A.
    Salem, Ahmed H.
    Munasinghe, Wijith
    Zhu, Ming
    Leverson, Joel
    Enschede, Sari H.
    Humerickhouse, Rod
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [46] Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
    Davids, Matthew S.
    Kim, Haesook T.
    Nicotra, Alyssa
    Savell, Alexandra
    Francoeur, Karen
    Hellman, Jeffrey M.
    Bazemore, Josie
    Miskin, Hari P.
    Sportelli, Peter
    Stampleman, Laura
    Maegawa, Rodrigo
    Rueter, Jens
    Boruchov, Adam M.
    Arnason, Jon E.
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Fisher, David C.
    Brown, Jennifer R.
    LANCET HAEMATOLOGY, 2019, 6 (01): : E38 - E47
  • [47] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
  • [48] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
    Ma, Shuo
    Brander, Danielle M.
    Seymour, John F.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Choi, Michael Y.
    Tam, Constantine S.
    Mason-Bright, Tanita
    Prine, Betty
    Munasinghe, Wijith
    Zhu, Ming
    Kim, Su Young
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2015, 126 (23)
  • [49] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
  • [50] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
12345